Therefore, the Mettl3/Pfkfb3/lactate/H3K18la/PD-L1 pathway was a common mechanism underlying the development of both renal fibrosis and tumor growth during repeated low-dose CDDP-based cancer therapy. The gene discussed is PFKFB3; the disease is cancer.